cisatracurium besylate injection
caplin steriles limited - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: • as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age • to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu • to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older. limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate have been reported [see warnings and precautions (5.4)] . the use of 10 ml cisatracurium besylate multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains ben
cisatracurium omega single dose solution
omega laboratories limited - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents
cisatracurium omega multidose solution
omega laboratories limited - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents
cisatracurium besylate injection solution
pfizer canada ulc - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents
cisatracurium besylate injection solution
mylan pharmaceuticals ulc - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents
cisatracurium besylate injection (preservative-free) solution
mylan pharmaceuticals ulc - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents
cisatracurium besylate injection single dose solution
fresenius kabi canada ltd - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents
cisatracurium besylate injection multi-dose solution
fresenius kabi canada ltd - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents
atracurium besilate injection 25 mg/2.5 ml vial
hospira australia pty ltd - atracurium besilate, quantity: 10 mg/ml - injection - excipient ingredients: water for injections; benzenesulfonic acid - atracurium besylate is indicated as an adjunct to general anesthesia, to facilitate endotrachael intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
cisatracurium apotex cisatracurium (as besilate) 5 mg / 2.5 ml solution for injection ampoule
arrotex pharmaceuticals pty ltd - cisatracurium besilate, quantity: 2.68 mg/ml (equivalent: cisatracurium, qty 2 mg/ml) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.